To identify and validate a novel gain-of-function mutation in the CASR gene associated with autosomal dominant hypocalcemia type 1 (ADH1) in a family with recurrent seizures, exploring the mutation's direct impact on seizure activity.
Key Findings:
A novel heterozygous CASR mutation, c.2452T>C (p.Trp818Arg), was identified, which has significant implications for understanding ADH1.
The proband experienced lifelong recurrent convulsive episodes misdiagnosed as epilepsy, highlighting the need for accurate genetic diagnosis.
Functional analyses confirmed the mutation resulted in a gain-of-function effect on CASR, which may contribute to the observed clinical symptoms.
Interpretation:
The findings underscore the importance of genetic testing in diagnosing ADH1, particularly in patients with unexplained recurrent seizures or hypocalcemia, suggesting potential for broader clinical applications.
Limitations:
The study is limited to a single family, which may not represent the broader population, potentially affecting the applicability of the findings.
Long-term outcomes of treatment were not assessed, which limits understanding of the mutation's impact over time.
Conclusion:
Genetic testing is crucial for diagnosing ADH1, and symptomatic treatment options include calcium supplementation and calcitriol to manage serum calcium levels, emphasizing the importance of early diagnosis.
A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness
